Inclusion Criteria:  Male or female, 30-65 years of age, inclusive at Visit 1. BMI of 18.0 to 31.9 kg/m², inclusive, at Visit 1. Have ≥3 weekly total symptom score obtained by combining ratings for abdominal bloating, flatulence, and burping from the GITQ. Consumes a typical American diet.  Exclusion Criteria:  Abnormal laboratory test results of clinical significance at Visit 1. Clinically important GI condition that would potentially interfere with the evaluation of the study product. Recent (within 2 weeks of Visit 1) history of an episode of acute GI illness such as nausea/vomiting or diarrhea. Self-reported history (within 6 weeks of Visit 1) of constipation or diarrhea. Uncontrolled and/or clinically important pulmonary (including uncontrolled asthma), cardiac (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), hepatic, renal, endocrine (including Type 1 and Type 2 diabetes mellitus), hematologic, immunologic, neurologic (such as Alzheimer's or Parkinson's disease), psychiatric (including depression and/or anxiety disorders) or biliary disorders. Uncontrolled hypertension as defined by the blood pressure measured at Visit 1. Have received a COVID vaccine within 2 weeks of Visit 2 or expected to receive a COVID vaccine during the study period. Had a positive SARS-CoV-2 test and experienced symptoms for >2 months. History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer. Weight loss or gain >4.5 kg in the 3 months prior to Visit 1. Antibiotic use within 3 months of Visit 1 and throughout the study period. Use of steroids within 1 month of Visit 1 and throughout the study period. Chronic use (i.e., daily on a regular basis) of anti-inflammatory medications (e.g., NSAIDS) within 1 month of Visit 1. Use of medications (over-the-counter or prescription) and/or dietary supplements, known to influence GI function.